Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study

Abstract

Objectives To determine the prevalence of organ impairment in long COVID patients at 6 and 12 months after initial symptoms and to explore links to clinical presentation. Design Prospective cohort study. Participants Individuals. Methods In individuals recovered from acute COVID-19, we assessed symptoms, health status, and multi-organ tissue characterisation and function. Setting Two non-acute healthcare settings (Oxford and London). Physiological and biochemical investigations were performed at baseline on all individuals, and those with organ impairment were reassessed. Main outcome measures Primary outcome was prevalence of single- and multi-organ impairment at 6 and 12 months post COVID-19. Results A total of 536 individuals (mean age 45 years, 73% female, 89% white, 32% healthcare workers, 13% acute COVID-19 hospitalisation) completed baseline assessment (median: 6 months post COVID-19); 331 (62%) with organ impairment or incidental findings had follow-up, with reduced symptom burden from baseline (median number of symptoms 10 and 3, at 6 and 12 months, respectively). Extreme breathlessness (38% and 30%), cognitive dysfunction (48% and 38%) and poor health-related quality of life (EQ-5D-5L < 0.7; 57% and 45%) were common at 6 and 12 months, and associated with female gender, younger age and single-organ impairment. Single- and multi-organ impairment were present in 69% and 23% at baseline, persisting in 59% and 27% at follow-up, respectively. Conclusions Organ impairment persisted in 59% of 331 individuals followed up at 1 year post COVID-19, with implications for symptoms, quality of life and longer-term health, signalling the need for prevention and integrated care of long COVID. Trial Registration: ClinicalTrials.gov Identifier: NCT04369807

Allergic diseases as risk factors for Long‐COVID symptoms: Systematic review of prospective cohort studies

“…[18][19][20] Clinical treatment pathways remain unclear and there are currently no proven, evidence-based treatment modalities yet, for either subgroups or the entire LC population. 21 Identifying the causes of LC symptoms is essential for targeted prevention and treatment, a crucial step towards avoiding long-term consequences and determining the rehabilitation needs of affected individuals.…”

What Role Does Microthrombosis Play in Long COVID?

“…Dennis et al 79 followed patients with acute COVID-19 with MRI and demonstrated structural damage to many organs 6 to 12 months after infection with 59% at 1 year. Injury was more common in patients with persisting symptoms than in asymptomatic patients, and liver steatosis was the most common finding.…”

Strategies for the Management of Spike Protein-Related Pathology

“…Although no official definition exists for 'post-Covid-Vaccine Syndrome,' a temporal correlation between receiving a Covid-19 vaccine and the beginning or worsening of a patient's clinical manifestations is sufficient to make the diagnosis of a Covid-19 vaccineinduced injury when the symptoms are unexplained by other concurrent causes. It should however be recognized that there is a significant overlap between the symptoms and features of the long Covid syndrome [167] and the post-Covid-Vaccine Syndrome [168]. However, a number of clinical features appear to be distinctive of the post-Covid vaccine syndrome; most notably, severe neurological symptoms (particularly small fiber neuropathy) appears to be more common following vaccination [169][170][171].…”